These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30718867)

  • 41. The Biosimilar Pipeline Seams Seem To Be Bursting.
    Reinke T
    Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2011 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
    [No Abstract]   [Full Text] [Related]  

  • 44. Fresh from the biotech pipeline: record-breaking FDA approvals.
    Senior M
    Nat Biotechnol; 2024 Mar; 42(3):355-361. PubMed ID: 38409589
    [No Abstract]   [Full Text] [Related]  

  • 45. The Orphan Drug Act Revisited.
    Thomas S; Caplan A
    JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
    [No Abstract]   [Full Text] [Related]  

  • 46. Aimovig for Migraine Prevention: The New Kid May Have Trouble Fitting in.
    Reinke T
    Manag Care; 2018 Jul; 27(7):10-11. PubMed ID: 29989892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The brave new world of biosimilars ('similar biologics') in India.
    Jois R
    Postgrad Med J; 2017 Oct; 93(1104):577-579. PubMed ID: 28546231
    [No Abstract]   [Full Text] [Related]  

  • 48. Pipelines turn to biotech.
    Lawrence S
    Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
    [No Abstract]   [Full Text] [Related]  

  • 49. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 50. Drugs that made headlines in 2015.
    Chakradhar S
    Nat Med; 2015 Dec; 21(12):1382-3. PubMed ID: 26646488
    [No Abstract]   [Full Text] [Related]  

  • 51. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.
    Cohen MH; Moses ML; Pazdur R
    Oncologist; 2002; 7(5):390-2. PubMed ID: 12401900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frontiers in nonclinical drug development: biosimilars.
    Ryan AM
    Vet Pathol; 2015 Mar; 52(2):419-26. PubMed ID: 25161206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biotech industry struggles with generics approval.
    Knight J
    Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
    [No Abstract]   [Full Text] [Related]  

  • 55. Drug pipeline 3Q18.
    DeFrancesco L
    Nat Biotechnol; 2018 Dec; 36(12):1132. PubMed ID: 30520867
    [No Abstract]   [Full Text] [Related]  

  • 56. Hints on preparing successful orphan drug designation requests.
    Buday PV
    Food Drug Law J; 1996; 51(1):75-84. PubMed ID: 11794354
    [No Abstract]   [Full Text] [Related]  

  • 57. Electoral campaign delays resolution of biotech issues.
    Fox JL
    Nat Biotechnol; 2004 Oct; 22(10):1193. PubMed ID: 15470439
    [No Abstract]   [Full Text] [Related]  

  • 58. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 59. Adoption agents.
    Wapner J
    Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
    [No Abstract]   [Full Text] [Related]  

  • 60. The Orphan Drug Act: an engine of innovation? At what cost?
    Rohde DD
    Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.